A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...

Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

Home-based phototherapy for plaque and guttate psoriasis is as effective as office-based phototherapy, results of the ...

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...